Cargando…

Case Report: Rapid renal response to venetoclax monotherapy in a CLL patient with secondary membranous glomerulonephritis

Membranous glomerulonephritis (MGN) is a rare extra-hematological autoimmune complication of chronic lymphocytic leukemia (CLL), clinically characterized by nephrotic-range proteinuria and, less frequently, renal failure. Because of the rarity of this condition, there is no standardized treatment. C...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lovato, Ester, Gangemi, Concetta, Krampera, Mauro, Visco, Carlo, Ferrarini, Isacco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10160354/ https://www.ncbi.nlm.nih.gov/pubmed/37152058 http://dx.doi.org/10.3389/fonc.2023.1108994

Ejemplares similares

An updated portrait of monocyte-macrophages in classical Hodgkin lymphoma
por: Ferrarini, Isacco, et al.
Publicado: (2023)

The Evolving Knowledge on T and NK Cells in Classic Hodgkin Lymphoma: Insights into Novel Subsets Populating the Immune Microenvironment
por: Ferrarini, Isacco, et al.
Publicado: (2020)

Oncogenic Mutations of MYD88 and CD79B in Diffuse Large B-Cell Lymphoma and Implications for Clinical Practice
por: Visco, Carlo, et al.
Publicado: (2020)

COVID-19 (SARS-CoV-2 infection) in lymphoma patients: A review
por: Bonuomo, Valentina, et al.
Publicado: (2021)

Review of Venetoclax in CLL, AML and Multiple Myeloma
por: Lasica, Masa, et al.
Publicado: (2021)

Case report: Successful treatment of refractory immune thrombocytopenia in chronic lymphocytic leukaemia with venetoclax monotherapy
por: Woo, Timothy, et al.
Publicado: (2023)

The mitochondrial anti-apoptotic dependencies of hematologic malignancies: from disease biology to advances in precision medicine
por: Ferrarini, Isacco, et al.
Publicado: (2022)

Two Distinct Clinical Patterns of Ibrutinib-to-Venetoclax Transition in Relapsed Chronic Lymphocytic Leukemia Patients
por: Ferrarini, Isacco, et al.
Publicado: (2022)

Update on the role of venetoclax and rituximab in the treatment of relapsed or refractory CLL
por: D’Rozario, James, et al.
Publicado: (2019)

Venetoclax: A Novel Therapeutic Agent for CLL with CNS Involvement
por: Karbhari, Nishika, et al.
Publicado: (2022)

Progressive Multifocal Leukoencephalopathy in B-CLL Successfully Treated With Venetoclax and Pembrolizumab
por: Olivieri, Jacopo, et al.
Publicado: (2022)

P650: EFFECTIVENESS OF VENETOCLAX ACCORDING TO THE CHARACTERISTICS OF PATIENTS WITH CLL IN MONOTHERAPY AND COMBINATION WITH RITUXIMAB. INTERIM ANALYSIS OF REAL-LIFE DATA FROM VERONE STUDY
por: Ysebaert, Loïc, et al.
Publicado: (2023)

Successful Anti-CLL1 CAR T-Cell Therapy in Secondary Acute Myeloid Leukemia
por: Zhang, Hui, et al.
Publicado: (2020)

Membranous glomerulonephritis secondary to syphilis
por: de Almeida Araújo, Stanley, et al.
Publicado: (2015)

COVID-19 among fit patients with CLL treated with venetoclax-based combinations
por: Fürstenau, Moritz, et al.
Publicado: (2020)

Mechanisms of venetoclax resistance and solutions
por: Liu, Jiachen, et al.
Publicado: (2022)

Characterizing Features of Human Circulating B Cells Carrying CLL-Like Stereotyped Immunoglobulin Rearrangements
por: Bagnara, Davide, et al.
Publicado: (2022)

NF-kB and the CLL microenvironment
por: O’Donnell, Alice, et al.
Publicado: (2023)

Ibrutinib and venetoclax target distinct subpopulations of CLL cells: implication for residual disease eradication
por: Lu, Pin, et al.
Publicado: (2021)

Can Treatment with Venetoclax for Chronic Lymphocytic Leukemia (CLL) Result In Autoimmune Hemolytic Anemia?
por: Abdel-Samad, Nizar, et al.
Publicado: (2021)

PB1863: BRUIN CLL-322: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF FIXED DURATION PIRTOBRUTINIB+VENETOCLAX AND RITUXIMAB VS VENETOCLAX AND RITUXIMAB IN PREVIOUSLY TREATED CLL/SLL (TRIAL IN PROGRESS)
por: Mato, A. R., et al.
Publicado: (2022)

Editorial: Biology and treatment of high-risk CLL
por: Tausch, Eugen, et al.
Publicado: (2023)

P623: MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) OF PIRTOBRUTINIB VS VENETOCLAX CONTINUOUS MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY CLL PREVIOUSLY TREATED WITH A COVALENT BTK INHIBITOR
por: Al-Sawaf, Othman, et al.
Publicado: (2023)

Durable remissions with venetoclax monotherapy in secondary AML refractory to hypomethylating agents and high expression of BCL‐2 and/or BIM
por: Huemer, Florian, et al.
Publicado: (2019)

Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab
por: Seymour, John F., et al.
Publicado: (2022)

Depletion of CLL cells by venetoclax treatment reverses oxidative stress and impaired glycolysis in CD4 T cells
por: van Bruggen, J. A. C., et al.
Publicado: (2022)

Single-cell multiomics reveal the scale of multilayered adaptations enabling CLL relapse during venetoclax therapy
por: Thijssen, Rachel, et al.
Publicado: (2022)

Electrolyte disorders secondary to venetoclax
por: van der Lubbe, Nils, et al.
Publicado: (2020)

Combination of Venetoclax and Midostaurin Efficiently Suppressed Relapsed t(8;21)Acute Myeloid Leukemia With Mutant KIT After Failure of Venetoclax Plus Azacitidine Treatment
por: Li, Zheng, et al.
Publicado: (2022)

Aberrant Promoter Hypomethylation in CLL: Does It Matter for Disease Development?
por: Upchurch, Garland Michael, et al.
Publicado: (2016)

Impact of Low-Burden TP53 Mutations in the Management of CLL
por: Lazarian, Gregory, et al.
Publicado: (2022)

Biology and Treatment of High-Risk CLL: Significance of Complex Karyotype
por: Chatzikonstantinou, Thomas, et al.
Publicado: (2021)

Double remission of chronic lymphocytic leukemia and secondary acute myeloid leukemia after venetoclax monotherapy: A case report
por: Wang, Lei, et al.
Publicado: (2021)

In Vitro Sensitivity to Venetoclax and Microenvironment Protection in Hairy Cell Leukemia
por: Vereertbrugghen, Alexia, et al.
Publicado: (2021)

MRD in Venetoclax-Based Treatment for AML: Does it Really Matter?
por: Bernardi, Massimo, et al.
Publicado: (2022)

Immunophenotypic measurable residual disease monitoring in adult acute lymphoblastic leukemia patients undergoing allogeneic hematopoietic stem cell transplantation
por: Tecchio, Cristina, et al.
Publicado: (2023)

Rapidly progressive glomerulonephritis due to coexistent anti-glomerular basement membrane disease and fibrillary glomerulonephritis
por: Cheungpasitporn, Wisit, et al.
Publicado: (2016)

Targeting ATM-deficient CLL through interference with DNA repair pathways
por: Knittel, Gero, et al.
Publicado: (2015)

Opinion: What defines high-risk CLL in the post-chemoimmunotherapy era?
por: Edelmann, Jennifer, et al.
Publicado: (2023)

PB2353: HEALTHCARE RESOURCE UTILIZATION AND COSTS OFF THERAPY WITH FIXED-DURATION VENETOCLAX AMONG CLL PATIENTS
por: Allan, J. N., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ltg7n9gis4gkfe4v63ot6vhapf